Zulekha Hamid, MD
Endocrinology, Diabetes & Metabolism · Little Rock, ARNPI 1134214893
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 193 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in AR, where the typical reported total is $5,363.
Across 193 payments — averaging $27.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$691
- Novo Nordisk$468
- AbbVie$400
- Kyowa Kirin, Inc.$389
- Lilly USA, LLC$337
- Corcept Therapeutics$286
- plus $3K from 24 others
What the payments were for
- Food & beverage$5,17296%
- Education$1914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 23 | $691 |
| Novo Nordisk | 12 | $468 |
| AbbVie | 14 | $400 |
| Kyowa Kirin, Inc. | 4 | $389 |
| Lilly USA, LLC | 17 | $337 |
| Corcept Therapeutics | 6 | $286 |
| Medtronic(2 entities) | 2 | $274 |
| Dexcom, Inc. | 35 | $265 |
| Abbott | 13 | $255 |
| Radius Health, Inc. | 6 | $240 |
| Bayer | 9 | $237 |
| Cequr Corporation | 1 | $198 |
| Boehringer Ingelheim | 5 | $181 |
| Insulet Corporation | 2 | $175 |
| Novartis | 9 | $149 |
| BETA Bionics, Inc. | 5 | $135 |
| Xeris Pharmaceuticals, Inc. | 7 | $129 |
| AstraZeneca | 2 | $111 |
| Sanofi-aventis U.S. LLC | 6 | $103 |
| Astellas Pharma US Inc | 1 | $96 |
| Nevro Corp. | 4 | $58 |
| Sequel Med Tech, LLC | 2 | $37 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Rhythm Pharmaceuticals, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Globus Medical | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,363 in reported general payments places this provider in the 50th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
See all endocrinology, diabetes & metabolism providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 434 | $459,216 |
| JardianceEmpagliflozin | 388 | $297,948 |
| TrulicityDulaglutide | 202 | $247,983 |
| FarxigaDapagliflozin Propanediol | 283 | $228,230 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 139 | $107,841 |
| MounjaroTirzepatide | 84 | $103,848 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 215 | $89,877 |
| Tresiba Flextouch U-100Insulin Degludec | 136 | $76,192 |
| Humalog Kwikpen U-100Insulin Lispro | 185 | $56,598 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 427 | $48,124 |
| Novolog FlexpenInsulin Aspart | 219 | $47,820 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 74 | $47,774 |
| Humulin R U-500Insulin Regular, Human | 17 | $47,089 |
| SynthroidLevothyroxine Sodium | 621 | $46,663 |
| Tresiba Flextouch U-200Insulin Degludec | 38 | $46,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $468 | $464,354470 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $337 | $351,830286 claims |
| Boehringer IngelheimJardiance | $181 | $297,948388 claims |
| AstraZenecaFarxiga | $111 | $228,230283 claims |
| AbbVieSynthroid | $400 | $46,663621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 43 endocrinology, diabetes & metabolism providers in Arkansas.
Other endocrinology, diabetes & metabolism in Little Rock
- Richard GriffithsLittle Rock$925K
- James ThrasherLittle Rock$349K
- Richard RappLittle Rock$47K
- Shunzhong BaoLittle Rock$40K
- Teresa NimmoLittle Rock$29K
- Madhu BudhrajaLittle Rock$29K
- Joseph HenskeLittle Rock$23K
- Nidhi JainLittle Rock$9K
- Archana JarathiLittle Rock$7K
- Allen ReddingLittle Rock$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.